Advanced Pharmacology Practice Exam
2026/2027 | 100 Board-Style Questions with
Answers & Explanations for NP, PA, MD,
PharmD Students
Description:
Master advanced pharmacology with this comprehensive 2026/2027 practice exam featuring
100 high-yield board-style questions, detailed clinical explanations, and evidence-based answers
covering endocrinology, psychopharmacology, neurology, infectious disease, and drug
interactions. Essential study guide for NP, PA, medical, nursing, and pharmacy students
preparing for board certification.
Download now and ace your pharmacology boards!
, Advanced Pharmacology Exam 2026/2027: 100 Practice Questions
SECTION A: ENDOCRINE PHARMACOLOGY AND HORMONE THERAPY
Question 1
A 62-year-old postmenopausal woman with a history of osteoporosis and an elevated risk of
venous thromboembolism is seeking non-hormonal alternatives for managing menopausal
symptoms. Which of the following agents would be most appropriate for this patient?
A) Conjugated equine estrogens
B) Medroxyprogesterone acetate
C) Raloxifene
D) Testosterone patch
E) Estradiol vaginal ring
Answer: C) Raloxifene
Explanation: Raloxifene is a selective estrogen receptor modulator (SERM) that provides
beneficial effects on bone mineral density while avoiding the endometrial stimulation and
thromboembolic risks associated with traditional hormone replacement therapy. Unlike estrogen,
raloxifene does not increase the risk of breast or endometrial cancer and is specifically indicated
for osteoporosis prevention and treatment in postmenopausal women.
Question 2
A clinician is evaluating treatment options for a patient with dysfunctional uterine bleeding who
requires hormonal management. Which therapeutic approach represents the standard initial
management strategy?
A) Continuous combined oral contraceptive therapy
B) 10 to 14-day course of progestin
C) Gonadotropin-releasing hormone agonists
,D) Estrogen-only therapy
E) Selective estrogen receptor modulators
Answer: B) 10 to 14-day course of progestin
Explanation: A 10 to 14-day course of progestin is the standard first-line approach for managing
dysfunctional uterine bleeding. This regimen helps stabilize the endometrial lining and control
bleeding episodes. Progestin therapy works by converting a proliferative endometrium to a
secretory state, thereby reducing excessive bleeding.
Question 3
A 24-year-old female presents with secondary amenorrhea and laboratory findings indicating
low estrogen levels. The most appropriate progestin regimen for inducing menstrual flow would
be:
A) Progestin administered for 14 days
B) Progestin administered for 5 to 10 days
C) Continuous progestin therapy
D) Intermittent progestin administration every other day
E) High-dose progestin for 3 days
Answer: B) Progestin administered for 5 to 10 days
Explanation: When estrogen levels are low in patients with amenorrhea, a 5 to 10-day course of
progestin is appropriate for inducing withdrawal bleeding. This shorter course is sufficient to
evaluate the endometrial response and assess the hypothalamic-pituitary-ovarian axis function. A
positive withdrawal bleed indicates adequate endogenous estrogen priming.
, Question 4
Which of the following statements accurately describes the rationale for long-term progestin
therapy in women with an intact uterus receiving estrogen replacement?
A) Progestin enhances the beneficial effects of estrogen on bone density
B) Progestin provides protection against endometrial cancer
C) Progestin reduces the risk of breast cancer
D) Progestin improves cardiovascular outcomes
E) Progestin eliminates the need for regular gynecological monitoring
Answer: B) Progestin provides protection against endometrial cancer
Explanation: Long-term progestin therapy is essential in women with an intact uterus who are
receiving estrogen replacement because unopposed estrogen increases the risk of endometrial
hyperplasia and carcinoma. Progestin counteracts estrogen-induced endometrial proliferation by
promoting secretory transformation and regular shedding of the endometrium.
Question 5
Among the following estrogen formulations, which compound demonstrates the highest
biological activity and is considered the most potent naturally occurring estrogen?
A) Estrone
B) Estriol
C) Estradiol
D) Ethinyl estradiol
E) Equilin
Answer: C) Estradiol
Explanation: Estradiol (17β-estradiol) is the most potent naturally occurring estrogen and serves
as the primary estrogen produced by the ovaries. It is significantly more active than estrone and
2026/2027 | 100 Board-Style Questions with
Answers & Explanations for NP, PA, MD,
PharmD Students
Description:
Master advanced pharmacology with this comprehensive 2026/2027 practice exam featuring
100 high-yield board-style questions, detailed clinical explanations, and evidence-based answers
covering endocrinology, psychopharmacology, neurology, infectious disease, and drug
interactions. Essential study guide for NP, PA, medical, nursing, and pharmacy students
preparing for board certification.
Download now and ace your pharmacology boards!
, Advanced Pharmacology Exam 2026/2027: 100 Practice Questions
SECTION A: ENDOCRINE PHARMACOLOGY AND HORMONE THERAPY
Question 1
A 62-year-old postmenopausal woman with a history of osteoporosis and an elevated risk of
venous thromboembolism is seeking non-hormonal alternatives for managing menopausal
symptoms. Which of the following agents would be most appropriate for this patient?
A) Conjugated equine estrogens
B) Medroxyprogesterone acetate
C) Raloxifene
D) Testosterone patch
E) Estradiol vaginal ring
Answer: C) Raloxifene
Explanation: Raloxifene is a selective estrogen receptor modulator (SERM) that provides
beneficial effects on bone mineral density while avoiding the endometrial stimulation and
thromboembolic risks associated with traditional hormone replacement therapy. Unlike estrogen,
raloxifene does not increase the risk of breast or endometrial cancer and is specifically indicated
for osteoporosis prevention and treatment in postmenopausal women.
Question 2
A clinician is evaluating treatment options for a patient with dysfunctional uterine bleeding who
requires hormonal management. Which therapeutic approach represents the standard initial
management strategy?
A) Continuous combined oral contraceptive therapy
B) 10 to 14-day course of progestin
C) Gonadotropin-releasing hormone agonists
,D) Estrogen-only therapy
E) Selective estrogen receptor modulators
Answer: B) 10 to 14-day course of progestin
Explanation: A 10 to 14-day course of progestin is the standard first-line approach for managing
dysfunctional uterine bleeding. This regimen helps stabilize the endometrial lining and control
bleeding episodes. Progestin therapy works by converting a proliferative endometrium to a
secretory state, thereby reducing excessive bleeding.
Question 3
A 24-year-old female presents with secondary amenorrhea and laboratory findings indicating
low estrogen levels. The most appropriate progestin regimen for inducing menstrual flow would
be:
A) Progestin administered for 14 days
B) Progestin administered for 5 to 10 days
C) Continuous progestin therapy
D) Intermittent progestin administration every other day
E) High-dose progestin for 3 days
Answer: B) Progestin administered for 5 to 10 days
Explanation: When estrogen levels are low in patients with amenorrhea, a 5 to 10-day course of
progestin is appropriate for inducing withdrawal bleeding. This shorter course is sufficient to
evaluate the endometrial response and assess the hypothalamic-pituitary-ovarian axis function. A
positive withdrawal bleed indicates adequate endogenous estrogen priming.
, Question 4
Which of the following statements accurately describes the rationale for long-term progestin
therapy in women with an intact uterus receiving estrogen replacement?
A) Progestin enhances the beneficial effects of estrogen on bone density
B) Progestin provides protection against endometrial cancer
C) Progestin reduces the risk of breast cancer
D) Progestin improves cardiovascular outcomes
E) Progestin eliminates the need for regular gynecological monitoring
Answer: B) Progestin provides protection against endometrial cancer
Explanation: Long-term progestin therapy is essential in women with an intact uterus who are
receiving estrogen replacement because unopposed estrogen increases the risk of endometrial
hyperplasia and carcinoma. Progestin counteracts estrogen-induced endometrial proliferation by
promoting secretory transformation and regular shedding of the endometrium.
Question 5
Among the following estrogen formulations, which compound demonstrates the highest
biological activity and is considered the most potent naturally occurring estrogen?
A) Estrone
B) Estriol
C) Estradiol
D) Ethinyl estradiol
E) Equilin
Answer: C) Estradiol
Explanation: Estradiol (17β-estradiol) is the most potent naturally occurring estrogen and serves
as the primary estrogen produced by the ovaries. It is significantly more active than estrone and
